Home » Topics » Ocular, BioWorld Science

Ocular, BioWorld Science
RSS

Xalatan approved in E.U. as first-line therapy for lowering IOP in glaucoma patients

April 24, 2002

ISTA to proceed with Vitrase NDA filing

April 12, 2002

Third phase III trial under way for INS-365 Ophthalmic in dry eye

April 9, 2002

Antiangiogenic effects demonstrated for CA4P in mouse model of proliferative retinopathy

April 4, 2002

Sucampo licenses development and marketing rights to eye drop formulation of tacrolimus

April 2, 2002

ISTA reports preliminary phase III results for Vitrase

March 28, 2002

ISTA updates clinical progress of Vitrase

March 19, 2002

Inhibition of iNOS provides neuroprotection in glaucoma

March 11, 2002

Functional and morphological effects of Epitalon in rat model of retinitis pigmentosa

March 11, 2002

Russian research yields polypeptide complex with efficacy in exudative AMD

March 11, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...